Publications by authors named "Zheyi Hu"

Claim this Profile
E
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.
Shengnan Du, Zheyi Hu, Jun Shen, Li Zhu, Amit Roy

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation.
Yue Zhao, Heather Vezina, Zheyi Hu, Anna Kondic, Li Zhu

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements.
Shengnan Du, Zheyi Hu, Jun Shen, Lora Hamuro, Justine Lam, Li Zhu

CPT Pharmacometrics Syst Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, Sarah Keidel, Karen Miller-Moslin

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect.
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Li Zhu

CPT Pharmacometrics Syst Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.
Shengnan Du, Yue Zhao, Zheyi Hu, Sihang Liu, Amit Roy, Li Zhu

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRUST-II: a global phase II study of taletrectinib in -positive non-small-cell lung cancer and other solid tumors.
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, Chang-Min Choi, Nong Yang, Zheyi Hu, Shuanglian Li

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Li Zhu

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition.
S Casey Laizure, Zhe-Yi Hu, Philip M Potter, Robert B Parker

Xenobiotica· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Alexander Drilon, Siqing Fu, Manish R Patel, Marwan Fakih, Ding Wang, Byoung Chul Cho, Zheyi Hu, Katherine McArthur

Cancer Discov· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects.
S Casey Laizure, Bernd Meibohm, Kembral Nelson, Feng Chen, Zhe-Yi Hu

Br J Clin Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of caffeine and its three primary metabolites in human plasma by HPLC-ESI-MS/MS and clinical application.
Feng Chen, Zhe-Yi Hu, Robert B Parker, S Casey Laizure

Biomed Chromatogr· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous assay of multiple antibiotics in human plasma by LC-MS/MS: importance of optimizing formic acid concentration.
Feng Chen, Zhe-Yi Hu, S Casey Laizure, Joanna Q Hudson

Bioanalysis· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.
Jing-Tao Lu, Ying Cai, Feng Chen, Wei-Wei Jia, Zhe-Yi Hu

Eur J Drug Metab Pharmacokinet· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
Bradley A Boucher, Joanna Q Hudson, David M Hill, Joseph M Swanson, G Christopher Wood, Zhe-Yi Hu

Pharmacotherapy· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo.
Zheyi Hu, Zaigang Zhou, Yahui Hu, Jinhui Wu, Yunman Li, Wenlong Huang

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A4-mediated pharmacokinetic interactions in cancer therapy.
Dandan Tian, Zheyi Hu

Curr Drug Metab· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach.
Feng Chen, Zhe-Yi Hu, Wei-Wei Jia, Jing-Tao Lu, Yuan-Sheng Zhao

Curr Drug Metab· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial (thematic issue: study and prediction of pharmacokinetic drug-drug interactions).
Zhe-Yi Hu

Curr Drug Metab· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the highly variable agomelatine pharmacokinetics in Chinese healthy subjects to support bioequivalence study.
Qi Pei, Yan Wang, Zhe-Yi Hu, Shi-Kun Liu, Hong-Yi Tan, Jie Huang, Lu Huang

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of alcohol on human carboxylesterase drug metabolism.
Robert B Parker, Zhe-Yi Hu, Bernd Meibohm, S Casey Laizure

Clin Pharmacokinet· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-1416, a novel MDR reversing agent with possible reduced calcium antagonism.
Zaigang Zhou, Xiaolei Tang, Yifan Zhang, Zheyi Hu, Jinhui Wu, Yiqiao Hu

Pharmacol Rep· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
Zhe-Yi Hu, Andrea N Edginton, S Casey Laizure, Robert B Parker

Clin Pharmacokinet· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Zhe-Yi Hu, Jingtao Lu, Yuansheng Zhao

Br J Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.
Zhe-Yi Hu, S Casey Laizure, Vanessa L Herring, Robert B Parker

Rapid Commun Mass Spectrom· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis